Lead poisoning in children

Area of Science:

• Environmental Health
• Pediatric Toxicology
• Public Health

Background:

• Childhood lead exposure and body burden remain significant public health concerns in the U.S.
• Widespread blood lead screening identifies many at-risk children, but screening criteria and age targets are debated.
• Lead screening has been less effective in certain populations, including rural areas and HMOs.

Purpose of the Study:

• To evaluate the effectiveness of meso 2,3-dimercaptosuccinic acid (DMSA) for treating lead exposure in children.
• To assess the efficacy of DMSA in lowering blood lead concentrations within specific ranges.
• To highlight the ongoing importance of environmental lead reduction strategies.

Main Methods:

• Review of evidence on DMSA efficacy for lead chelation in children.
• Analysis of blood lead concentration data in relation to DMSA treatment.
• Consideration of current treatment guidelines and limitations.

Main Results:

• DMSA is approved for oral chelation in children with blood lead levels above 45 µg/dL.
• Evidence suggests DMSA effectively lowers blood lead levels in children with concentrations between 25 and 45 µg/dL.
• The long-term effectiveness of chelation at lower lead levels requires further investigation.

Conclusions:

• Meso 2,3-dimercaptosuccinic acid (DMSA) offers a treatment option for children with elevated lead levels.
• Environmental decontamination remains the primary and most critical intervention for preventing and treating childhood lead exposure.
• Further research is needed to determine the long-term benefits of DMSA chelation at lower blood lead concentrations.